Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Sci Adv ; 7(23)2021 06.
Article in English | MEDLINE | ID: mdl-34078606

ABSTRACT

The merozoite surface protein 1 (MSP-1) is the most abundant protein on the surface of the erythrocyte-invading Plasmodium merozoite, the causative agent of malaria. MSP-1 is essential for merozoite formation, entry into and escape from erythrocytes, and is a promising vaccine candidate. Here, we present monomeric and dimeric structures of full-length MSP-1. MSP-1 adopts an unusual fold with a large central cavity. Its fold includes several coiled-coils and shows structural homology to proteins associated with membrane and cytoskeleton interactions. MSP-1 formed dimers through these domains in a concentration-dependent manner. Dimerization is affected by the presence of the erythrocyte cytoskeleton protein spectrin, which may compete for the dimerization interface. Our work provides structural insights into the possible mode of interaction of MSP-1 with erythrocytes and establishes a framework for future investigations into the role of MSP-1 in Plasmodium infection and immunity.


Subject(s)
Malaria , Merozoite Surface Protein 1 , Amino Acid Sequence , Erythrocytes/metabolism , Humans , Malaria/metabolism , Merozoite Surface Protein 1/chemistry , Merozoite Surface Protein 1/metabolism , Plasmodium falciparum , Protozoan Proteins/chemistry
2.
NPJ Vaccines ; 5(1): 10, 2020.
Article in English | MEDLINE | ID: mdl-32025341

ABSTRACT

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) in combination with GLA-SE adjuvant. Thirty-two healthy volunteers were vaccinated at least three times with MSP1 plus adjuvant, adjuvant alone, or placebo (24:4:4) to evaluate the safety and immunogenicity. MSP1 was safe, well tolerated and immunogenic, with all vaccinees sero-converting independent of the dose. The MSP1-specific IgG and IgM titers persisted above levels found in malaria semi-immune humans for at least 6 months after the last immunization. The antibodies were variant- and strain-transcending and stimulated respiratory activity in granulocytes. Furthermore, full-length MSP1 induced memory T-cells. Our findings encourage challenge studies as the next step to evaluate the efficacy of full-length MSP1 as a vaccine candidate against falciparum malaria (EudraCT 2016-002463-33).

3.
Clin Vaccine Immunol ; 24(11)2017 Nov.
Article in English | MEDLINE | ID: mdl-28877929

ABSTRACT

Naturally acquired immunity against malaria is largely mediated by serum antibodies controlling levels of blood-stage parasites. A limited understanding of the antigenic targets and functional mechanisms of protective antibodies has hampered the development of efficient malaria vaccines. Besides directly inhibiting the growth of Plasmodium parasites, antibodies can opsonize merozoites and recruit immune effector cells such as monocytes and neutrophils. Antibodies against the vaccine candidate merozoite surface protein 1 (MSP-1) are acquired during natural infections and have been associated with protection against malaria in several epidemiological studies. Here we analyzed serum antibodies from semi-immune individuals from Burkina Faso for their potential (i) to directly inhibit the growth of P. falciparum blood stages in vitro and (ii) to opsonize merozoites and to induce the antibody-dependent respiratory burst (ADRB) activity of neutrophils. While a few sera that directly inhibited the growth of P. falciparum blood stages were identified, immunoglobulin G (IgG) from all individuals clearly mediated the activation of neutrophils. The level of neutrophil activation correlated with levels of antibodies to MSP-1, and affinity-purified MSP-1-specific antibodies elicited ADRB activity. Furthermore, immunization of nonhuman primates with recombinant full-size MSP-1 induced antibodies that efficiently opsonized P. falciparum merozoites. Reversing the function by preincubation with recombinant antigens allowed us to quantify the contribution of MSP-1 to the antiparasitic effect of serum antibodies. Our data suggest that MSP-1, especially the partially conserved subunit MSP-183, is a major target of opsonizing antibodies acquired during natural exposure to malaria. Induction of opsonizing antibodies might be a crucial effector mechanism for MSP-1-based malaria vaccines.


Subject(s)
Adaptive Immunity , Antibodies, Protozoan/immunology , Malaria, Falciparum/immunology , Merozoite Surface Protein 1/immunology , Opsonin Proteins/immunology , Plasmodium falciparum/immunology , Animals , Antibodies, Protozoan/blood , Antigens, Protozoan/immunology , Burkina Faso/epidemiology , Humans , Immunoglobulin G/blood , Macaca mulatta , Malaria Vaccines/immunology , Malaria, Falciparum/epidemiology , Merozoites/chemistry , Merozoites/immunology , Neutrophil Activation , Neutrophils/immunology , Plasmodium falciparum/growth & development , Respiratory Burst
4.
J Biol Chem ; 291(14): 7703-15, 2016 Apr 01.
Article in English | MEDLINE | ID: mdl-26823464

ABSTRACT

Successful invasion of human erythrocytes byPlasmodium falciparummerozoites is required for infection of the host and parasite survival. The early stages of invasion are mediated via merozoite surface proteins that interact with human erythrocytes. The nature of these interactions are currently not well understood, but it is known that merozoite surface protein 1 (MSP1) is critical for successful erythrocyte invasion. Here we show that the peripheral merozoite surface proteins MSP3, MSP6, MSPDBL1, MSPDBL2, and MSP7 bind directly to MSP1, but independently of each other, to form multiple forms of the MSP1 complex on the parasite surface. These complexes have overlapping functions that interact directly with human erythrocytes. We also show that targeting the p83 fragment of MSP1 using inhibitory antibodies inhibits all forms of MSP1 complexes and disrupts parasite growthin vitro.


Subject(s)
Erythrocytes/metabolism , Merozoite Surface Protein 1/metabolism , Merozoites/metabolism , Multiprotein Complexes/metabolism , Plasmodium falciparum/metabolism , Erythrocytes/parasitology , Humans
5.
J Biol Chem ; 289(37): 25655-69, 2014 Sep 12.
Article in English | MEDLINE | ID: mdl-25074930

ABSTRACT

Plasmodium falciparum is the causative agent of the most severe form of malaria in humans. The merozoite, an extracellular stage of the parasite lifecycle, invades erythrocytes in which they develop. The most abundant protein on the surface of merozoites is merozoite surface protein 1 (MSP1), which consists of four processed fragments. Studies indicate that MSP1 interacts with other peripheral merozoite surface proteins to form a large complex. Successful invasion of merozoites into host erythrocytes is dependent on this protein complex; however, the identity of all components and its function remain largely unknown. We have shown that the peripheral merozoite surface proteins MSPDBL1 and MSPDBL2 are part of the large MSP1 complex. Using surface plasmon resonance, we determined the binding affinities of MSPDBL1 and MSPDBL2 to MSP1 to be in the range of 2-4 × 10(-7) m. Both proteins bound to three of the four proteolytically cleaved fragments of MSP1 (p42, p38, and p83). In addition, MSPDBL1 and MSPDBL2, but not MSP1, bound directly to human erythrocytes. This demonstrates that the MSP1 complex acts as a platform for display of MSPDBL1 and MSPDBL2 on the merozoite surface for binding to receptors on the erythrocyte and invasion.


Subject(s)
Malaria/metabolism , Merozoite Surface Protein 1/metabolism , Merozoites/chemistry , Plasmodium falciparum/metabolism , Protozoan Proteins/metabolism , Animals , Erythrocytes/chemistry , Erythrocytes/parasitology , Humans , Malaria/parasitology , Malaria/pathology , Membrane Proteins/genetics , Membrane Proteins/metabolism , Merozoite Surface Protein 1/chemistry , Multiprotein Complexes/chemistry , Multiprotein Complexes/metabolism , Plasmodium falciparum/pathogenicity , Protein Binding
6.
Epigenetics ; 8(11): 1226-35, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24071829

ABSTRACT

The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the "cellular ratio of immune tolerance" (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.


Subject(s)
Biomarkers, Tumor/immunology , Immune Tolerance , Neoplasms/immunology , Neoplasms/pathology , Adult , Aged , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Case-Control Studies , Colorectal Neoplasms/immunology , Colorectal Neoplasms/pathology , Epigenesis, Genetic , Female , Humans , Kidney Neoplasms/immunology , Kidney Neoplasms/pathology , Lung Neoplasms/immunology , Lung Neoplasms/pathology , Middle Aged , Neoplasm Metastasis , Ovarian Neoplasms/immunology , Ovarian Neoplasms/pathology , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Young Adult
7.
BMC Biol ; 10: 77, 2012 Sep 03.
Article in English | MEDLINE | ID: mdl-22943311

ABSTRACT

BACKGROUND: Turning gene expression on and off at will is one of the most powerful tools for the study of gene function in vivo. While several conditional systems were successful in invertebrates, in mice the Cre/loxP recombination system and the tet-controlled transcription activation system are predominant. Both expression systems allow for spatial and temporal control of gene activities, and, in the case of tet regulation, even for the reversible activation/inactivation of gene expression. Although the rat is the principal experimental model in biomedical research, in particular in studies of neuroscience, conditional rat transgenic systems are exceptionally rare in this species. RESULTS: We addressed this lack of technology, and established and thoroughly characterized CreERT2 and tTA transgenic rats with forebrain-specific transgene expression, controlled by the CaMKII alpha promoter. In addition, we developed new universal rat reporter lines for both transcription control systems and established inducible and efficient reporter gene expression in forebrain neurons. CONCLUSIONS: We demonstrate that conditional genetic manipulations in the rat brain are both feasible and practicable and outline advantages and limitations of the Tet and Cre/loxP system in the rat brain.


Subject(s)
Brain/metabolism , Gene Expression , Animals , Brain/drug effects , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Doxycycline/pharmacology , Gene Expression/drug effects , Genes, Reporter , Green Fluorescent Proteins/metabolism , Integrases/metabolism , Luciferases/metabolism , Mice , Rats , Rats, Transgenic , Recombination, Genetic/genetics , Tamoxifen/pharmacology , Tetracycline/pharmacology , beta-Galactosidase/metabolism
8.
J Gene Med ; 13(12): 670-9, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22095915

ABSTRACT

BACKGROUND: The merozoite surface protein (MSP)-1 of Plasmodium falciparum, the causative agent of malaria tropica, is considered to be a promising vaccine candidate. Although its stable cloning and expression has been difficult in the past, adenoviral vectors expressing the complex protein are described in the present study. METHODS: Codon-optimized msp-1 was used to construct a set of first generation (ΔE1Ad) and high-capacity adenovirus (HC-Ad) vectors, and cellular and humoral immune responses induced by the vectors were characterized in detail in mice. RESULTS: Generation of stable ΔE1Ad and HC-Ad vectors expressing full-length MSP-1 and their production to high vector titers was found to be feasible. Epitope identification and analysis of frequencies of specific CD8 T-cells revealed that MSP-1 expressing HC-Ad vectors induced higher frequencies of interferon-γ + CD8 T-cells than ΔE1 vectors. Irrespective of the vector format, higher titers of MSP-1 specific antibodies were generated by Ad vectors expressing MSP-1 from a chicken ß-actin (CAG) promoter comprising the cytomegalovirus early enhancer element and the chicken ß-actin promoter. CONCLUSIONS: The findings of the present study suggest that Ad vectors expressing full-length codon-optimized MSP-1 are promising candidate vaccines against P. falciparum infections. Use of the HC-Ad vector type for delivery, as well as the CAG promoter to control MSP-1 expression, may further increase the efficacy of this vaccine candidate.


Subject(s)
Adenovirus Vaccines , Malaria, Falciparum/therapy , Merozoite Surface Protein 1 , Plasmodium falciparum , Adenovirus Vaccines/genetics , Adenovirus Vaccines/immunology , Adenovirus Vaccines/therapeutic use , Animals , Antibody Specificity , CD8-Positive T-Lymphocytes/immunology , Codon/genetics , Female , Genetic Vectors , Humans , Interferon-gamma/metabolism , Malaria, Falciparum/genetics , Merozoite Surface Protein 1/genetics , Merozoite Surface Protein 1/immunology , Merozoite Surface Protein 1/therapeutic use , Mice , Mice, Inbred BALB C , Plasmodium falciparum/immunology , Plasmodium falciparum/pathogenicity , Promoter Regions, Genetic
9.
Am J Respir Cell Mol Biol ; 44(2): 244-54, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20395635

ABSTRACT

Conditional regulation of gene expression by the combined use of a lung-specific promoter and the tetracycline-regulated system provides a powerful tool for studying gene function in lung biology and disease pathogenesis in a development-independent fashion. However, the original version of the reverse tetracycline-dependent transactivator (rtTA) exhibited limited doxycycline sensitivity and residual affinity to its promoter (P(tet)), producing leaky transgene expression in the absence of doxycycline. These limitations impeded the use of this system in studying gene dosage effects in pulmonary pathogenesis and repair mechanisms in the diseased lung. Therefore, we used a new-generation rtTA, rtTA2(s)-M2, with no basal activity and increased doxycycline sensitivity, and the rat Clara cell secretory protein (CCSP) promoter to target its expression to pulmonary epithelia in mice. Novel CCSP-rtTA2(s)-M2 founder lines were crossed, with bi-transgenic reporter mice expressing luciferase and Cre recombinase. Background activity, doxycycline sensitivity, tissue and cell-type specificity, inducibility, and reversibility of doxycycline-dependent gene expression were determined by luciferase activity, immunohistochemistry, morphometry, and bioluminescence measurements in neonatal and adult lungs. We generated two distinct novel CCSP-rtTA2(s)-M2 activator mouse lines that confer tight and doxycycline dose-dependent regulation of transgene expression, with high inducibility, complete reversibility, and no background activity, in airway and alveolar epithelia. We conclude that rtTA2(s)-M2 enables quantitative control of conditional gene expression in respiratory epithelia of the murine lung, and that the new CCSP-rtTA2(s)-M2 activator mouse lines will be useful in the further elucidation of the pathogenesis of complex lung diseases and in studies of lung repair.


Subject(s)
Gene Expression/drug effects , Lung/drug effects , Lung/metabolism , Tetracycline/pharmacology , Trans-Activators/genetics , Animals , Animals, Newborn , Dose-Response Relationship, Drug , Doxycycline/administration & dosage , Doxycycline/pharmacology , Genetic Techniques , Integrases/genetics , Lung/growth & development , Mice , Mice, Inbred C57BL , Mice, Transgenic , Organ Specificity , Promoter Regions, Genetic , Rats , Uteroglobin/genetics
10.
Transgenic Res ; 20(3): 709-20, 2011 Jun.
Article in English | MEDLINE | ID: mdl-20640885

ABSTRACT

The establishment of functional transgenic mouse lines is often limited by problems caused by integration site effects on the expression construct. Similarly, tetracycline (Tet) controlled transcription units most commonly used for conditional transgene expression in mice are strongly influenced by their genomic surrounding. Using bacterial artificial chromosome (BAC) technology in constitutive expression systems, it has been shown that integration site effects resulting in unwanted expression patterns can be largely eliminated. Here we describe a strategy to minimize unfavourable integration effects on conditional expression constructs based on a 75 kb genomic BAC fragment. This fragment was derived from a transgenic mouse line, termed LC-1, which carries the Tet-inducible genes luciferase and cre (Schönig et al. 2002). Animals of this mouse line have previously been shown to exhibit optimal expression properties in terms of tightness in the off state and the absolute level of induction, when mated to appropriate transactivator expressing mice. Here we report the cloning and identification of the transgenic LC-1 integration site which was subsequently inserted into a bacterial artificial chromosome. We demonstrate that this vector facilitates the efficient generation of transgenic mouse and rat lines, where the Tet-controlled expression unit is shielded from perturbations caused by the integration site.


Subject(s)
Chromosomes, Artificial, Bacterial/genetics , Gene Expression Regulation , Genetic Vectors , Rodentia/genetics , Tetracycline/pharmacology , Transgenes/physiology , Animals , Animals, Genetically Modified/genetics , Animals, Genetically Modified/metabolism , Cell Line , Cloning, Molecular , Integrases/genetics , Integrases/metabolism , Luciferases/genetics , Luciferases/metabolism , Mice , Mice, Transgenic , Rats , Rodentia/metabolism , Transgenes/genetics
11.
BMC Biotechnol ; 10: 81, 2010 Nov 24.
Article in English | MEDLINE | ID: mdl-21106052

ABSTRACT

BACKGROUND: The performance of the tetracycline controlled transcriptional activation system (Tet system) depends critically on the choice of minimal promoters. They are indispensable to warrant low expression levels with the system turned "off". On the other hand, they must support high level of gene expression in the "on"-state. RESULTS: In this study, we systematically modified the widely used Cytomegalovirus (CMV) minimal promoter to further minimize background expression, resulting in an improved dynamic expression range. Using both plasmid-based and retroviral gene delivery, our analysis revealed that especially background expression levels could be significantly reduced when compared to previously established "standard" promoter designs. Our results also demonstrate the possibility to fine-tune expression levels in non-clonal cell populations. They also imply differences regarding the requirements for tight regulation and high level induction between transient and stable gene transfer systems. CONCLUSIONS: Until now, our understanding of mammalian transcriptional regulation including promoter architecture is limited. Nevertheless, the partly empirical modification of cis-elements as shown in this study can lead to the specific improvement of the performance of minimal promoters. The novel composite Ptet promoters introduced here will further expand the utility of the Tet system.


Subject(s)
Gene Expression Regulation/drug effects , Promoter Regions, Genetic/drug effects , Tetracycline/pharmacology , Cell Line , Genetic Vectors , Humans , Transduction, Genetic , Transgenes
12.
Mol Microbiol ; 78(1): 187-202, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20735778

ABSTRACT

The malaria parasite Plasmodium falciparum invades erythrocytes where it replicates to produce invasive merozoites, which eventually egress to repeat the cycle. Merozoite surface protein-1 (MSP1), a prime malaria vaccine candidate and one of the most abundant components of the merozoite surface, is implicated in the ligand-receptor interactions leading to invasion. MSP1 is extensively proteolytically modified, first just before egress and then during invasion. These primary and secondary processing events are mediated respectively, by two parasite subtilisin-like proteases, PfSUB1 and PfSUB2, but the function and biological importance of the processing is unknown. Here, we examine the regulation and significance of MSP1 processing. We show that primary processing is ordered, with the primary processing site closest to the C-terminal end of MSP1 being cleaved last, irrespective of polymorphisms throughout the rest of the molecule. Replacement of the secondary processing site, normally refractory to PfSUB1, with a PfSUB1-sensitive site, is deleterious to parasite growth. Our findings show that correct spatiotemporal regulation of MSP1 maturation is crucial for the function of the protein and for maintenance of the parasite asexual blood-stage life cycle.


Subject(s)
Merozoite Surface Protein 1/metabolism , Plasmodium falciparum/physiology , Protozoan Proteins/metabolism , Subtilisin/metabolism , Plasmodium falciparum/growth & development , Protein Processing, Post-Translational
13.
Methods Enzymol ; 477: 429-53, 2010.
Article in English | MEDLINE | ID: mdl-20699154

ABSTRACT

Tetracycline-controlled transcriptional activation systems are widely used to control gene expression in transgenic animals in a truly conditional manner. By this we refer to the capability of these expression systems to control gene activities not only in a tissue specific and temporal defined but also reversible manner. This versatility has made the Tet regulatory systems to a preeminent tool in reverse mouse genetics. The development of the technology in the past 15 years will be reviewed and guidelines will be given for its implementation in creating transgenic rodents. Finally, we highlight some recent exciting applications of the Tet technology as well as its foreseeable combination with other emerging technologies in mouse transgenesis.


Subject(s)
RNA Interference/physiology , Tetracycline/pharmacology , Transcription, Genetic/genetics , Animals , Mice , Mice, Transgenic , Transcription, Genetic/drug effects
14.
Malar J ; 9: 77, 2010 Mar 18.
Article in English | MEDLINE | ID: mdl-20298576

ABSTRACT

BACKGROUND: Plasmodium falciparum merozoites expose at their surface a large protein complex, which is composed of fragments of merozoite surface protein 1 (MSP-1; called MSP-183, MSP-130, MSP-138, and MSP-142) plus associated processing products of MSP-6 and MSP-7. During erythrocyte invasion this complex, as well as an integral membrane protein called apical membrane antigen-1 (AMA-1), is shed from the parasite surface following specific proteolysis. Components of the MSP-1/6/7 complex and AMA-1 are presently under development as malaria vaccines. METHODS: The specificities and effects of antibodies directed against MSP-1, MSP-6, MSP-7 on the growth of blood stage parasites were studied using ELISA and the pLDH-assay. To understand the mode of action of these antibodies, their effects on processing of MSP-1 and AMA-1 on the surface of merozoites were investigated. RESULTS: Antibodies targeting epitopes located throughout the MSP-1/6/7 complex interfere with shedding of MSP-1, and as a consequence prevent erythrocyte invasion. Antibodies targeting the MSP-1/6/7 complex have no effect on the processing and shedding of AMA-1 and, similarly, antibodies blocking the shedding of AMA-1 do not affect cleavage of MSP-1, suggesting completely independent functions of these proteins during invasion. Furthermore, some epitopes, although eliciting highly inhibitory antibodies, are only poorly recognized by the immune system when presented in the structural context of the intact antigen. CONCLUSIONS: The findings reported provide further support for the development of vaccines based on MSP-1/6/7 and AMA-1, which would possibly include a combination of these antigens.


Subject(s)
Antibodies, Monoclonal/immunology , Antigens, Protozoan/immunology , Membrane Proteins/immunology , Merozoite Surface Protein 1/immunology , Plasmodium falciparum/parasitology , Protozoan Proteins/immunology , Animals , Antibodies, Monoclonal/metabolism , Antibodies, Protozoan/blood , Antibodies, Protozoan/immunology , Antibody Specificity , Antigens, Surface/immunology , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Epitopes/immunology , Erythrocytes/metabolism , Erythrocytes/parasitology , Humans , Immunoglobulin G , Malaria Vaccines/immunology , Mice , Rabbits
15.
Genesis ; 47(11): 729-35, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19621440

ABSTRACT

The generation of cell type specific inducible Cre transgenic mice is the most challenging and limiting part in the development of spatio-temporally controlled knockout mouse models. Here we report the generation and characterization of a B lymphocyte-specific tamoxifen-inducible Cre transgenic mouse strain, LC-1-hCD19-CreER(T2). We utilized the human CD19 promoter for expression of the tamoxifen-inducible Cre recombinase (CreER(T2)) gene, embedded in genomic sequences previously reported to give minimal position effects after transgenesis. Cre recombinase activity was evaluated by cross-breeding the LC-1-hCD19-CreER(T2) strain with a strain containing a floxed gene widely expressed in the hematopoietic system. Cre activity was only detected in the presence of tamoxifen and was restricted to B lymphocytes. The efficacy of recombination ranged from 27 to 61% in the hemizygous and homozygous mice, respectively. In conclusion, the LC-1-hCD19-CreER(T2) strain is a powerful tool to study gene function specifically in B lymphocytes at any chosen time point in the lifecycle of the mouse.


Subject(s)
B-Lymphocytes/metabolism , Chromosomes, Artificial, Bacterial , Gene Expression Regulation/drug effects , Integrases/genetics , Tamoxifen/pharmacology , Transgenes , Animals , Antigens, CD19/genetics , Base Sequence , DNA Primers , Humans , Mice , Mice, Transgenic , Polymerase Chain Reaction
16.
J Immunol ; 182(9): 5453-60, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19380793

ABSTRACT

CD226 is known to be expressed on many types of peripheral lymphoid cells and involved in T cell differentiation, activation, and cytotoxicity. In this study, we report that CD226 is also expressed on mouse thymocytes at varying developmental stages, and its expression is associated with resistance of thymocytes to apoptosis. The levels of CD226 expression appeared to be closely coupled with thymocyte development, in that it was preferentially expressed on CD4(+)CD8(-) and CD4(-)CD8(+) thymocytes at all stages during mouse development, and was markedly increased on the cells in neonatal mice. Of the CD4(+)CD8(+) population, CD226 was predominantly expressed by the cells also positive for CD69, suggesting that CD226 expression may be induced in thymocyte-positive selection. Inhibition of CD226 by short hairpin RNA in a fetal thymus organ culture model led to reduced thymus cellularity, which was associated with enhanced apoptotic cell death. In contrast, CD226-transgenic mice displayed enlarged thymus lobes resulting from increased thymus cellularity. CD226 on thymocytes seemed to play a role in regulating the expression of survivin, as inhibition of CD226 down-regulated survivin, but overexpression of CD226 rescued thymocytes from apoptosis through up-regulation of survivin. In addition, overexpression of CD226 reduced sensitivity of EL-4 thymoma cells to apoptosis by up-regulating the expression of survivin. Taken together, these results indicate that CD226 is an antiapoptotic molecule and may play an important role in murine thymocyte development.


Subject(s)
Antigens, Differentiation, T-Lymphocyte/biosynthesis , Apoptosis/immunology , Inhibitor of Apoptosis Proteins/biosynthesis , Thymus Gland/cytology , Thymus Gland/immunology , Animals , Antigens, Differentiation, T-Lymphocyte/genetics , Antigens, Differentiation, T-Lymphocyte/physiology , Apoptosis/genetics , Cell Death/genetics , Cell Death/immunology , Cell Differentiation/genetics , Cell Differentiation/immunology , Cell Line , Cell Line, Tumor , Fetus , Humans , Inhibitor of Apoptosis Proteins/genetics , Inhibitor of Apoptosis Proteins/physiology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Organ Culture Techniques , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocyte Subsets/pathology , Thymus Gland/abnormalities , Thymus Gland/metabolism
17.
Nucleic Acids Res ; 37(7): e50, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19264799

ABSTRACT

Conditional gene expression systems have developed into essential tools for the study of gene functions. However, their utility is often limited by the difficulty of identifying clonal cell lines, in which transgene control can be realized to its full potential. Here, we describe HeLa cell lines, in which we have identified-by functional analysis-genomic loci, from which the expression of transgenes can be tightly controlled via tetracycline-regulated expression. These loci can be re-targeted by recombinase-mediated cassette exchange. Upon exchange of the gene of interest, the resulting cell line exhibits the qualitative and quantitative properties of controlled transgene expression characteristic for the parent cell line. Moreover, by using an appropriate promoter, these cell lines express the tetracycline controlled transcription activator rtTA2-M2 uniformly throughout the entire cell population. The potential of this approach for functional genomics is highlighted by utilizing one of our master cell lines for the efficient microRNA-mediated knockdown of the endogenous human lamin A/C gene.


Subject(s)
RNA Interference , Transcription, Genetic , Transgenes , Doxycycline/pharmacology , Gene Targeting , Genome, Human , HeLa Cells , Humans , Lamin Type A/genetics , Membrane Glycoproteins/genetics , MicroRNAs/genetics , MicroRNAs/metabolism , Peptide Elongation Factor 1/genetics , RNA, Messenger/metabolism , Trans-Activators/genetics , Trans-Activators/metabolism
18.
EMBO J ; 28(6): 725-35, 2009 Mar 18.
Article in English | MEDLINE | ID: mdl-19214190

ABSTRACT

The malaria parasite Plasmodium falciparum replicates within an intraerythrocytic parasitophorous vacuole (PV). Rupture of the host cell allows release (egress) of daughter merozoites, which invade fresh erythrocytes. We previously showed that a subtilisin-like protease called PfSUB1 regulates egress by being discharged into the PV in the final stages of merozoite development to proteolytically modify the SERA family of papain-like proteins. Here, we report that PfSUB1 has a further role in 'priming' the merozoite prior to invasion. The major protein complex on the merozoite surface comprises three proteins called merozoite surface protein 1 (MSP1), MSP6 and MSP7. We show that just before egress, all undergo proteolytic maturation by PfSUB1. Inhibition of PfSUB1 activity results in the accumulation of unprocessed MSPs on the merozoite surface, and erythrocyte invasion is significantly reduced. We propose that PfSUB1 is a multifunctional processing protease with an essential role in both egress of the malaria merozoite and remodelling of its surface in preparation for erythrocyte invasion.


Subject(s)
Erythrocytes/parasitology , Malaria, Falciparum/enzymology , Malaria, Falciparum/parasitology , Parasites/enzymology , Plasmodium falciparum/enzymology , Protozoan Proteins/metabolism , Serine Endopeptidases/metabolism , Subtilisins/metabolism , Amino Acid Motifs , Amino Acid Sequence , Animals , Consensus Sequence , Erythrocytes/drug effects , Humans , Merozoites/enzymology , Molecular Sequence Data , Parasites/drug effects , Peptides/metabolism , Plasmodium falciparum/drug effects , Protein Processing, Post-Translational/drug effects , Protozoan Proteins/antagonists & inhibitors , Protozoan Proteins/chemistry , Recombinant Proteins/metabolism , Serine Endopeptidases/chemistry , Serine Proteinase Inhibitors/pharmacology , Substrate Specificity/drug effects , Subtilisins/antagonists & inhibitors , Subtilisins/chemistry
20.
Nat Med ; 14(9): 979-84, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18724376

ABSTRACT

We describe a transgenic mouse line, Pax8-rtTA, which, under control of the mouse Pax8 promoter, directs high levels of expression of the reverse tetracycline-dependent transactivator (rtTA) to all proximal and distal tubules and the entire collecting duct system of both embryonic and adult kidneys. Using crosses of Pax8-rtTA mice with tetracycline-responsive c-MYC mice, we established a new, inducible model of polycystic kidney disease that can mimic adult onset and that shows progression to renal malignant disease. When targeting the expression of transforming growth factor beta-1 to the kidney, we avoided early lethality by discontinuous treatment and successfully established an inducible model of renal fibrosis. Finally, a conditional knockout of the gene encoding tuberous sclerosis complex-1 was achieved, which resulted in the early outgrowth of giant polycystic kidneys reminiscent of autosomal recessive polycystic kidney disease. These experiments establish Pax8-rtTA mice as a powerful tool for modeling renal diseases in transgenic mice.


Subject(s)
Disease Models, Animal , Kidney Tubules/physiology , Polycystic Kidney Diseases/genetics , Trans-Activators/genetics , Animals , Doxycycline/blood , Doxycycline/metabolism , Doxycycline/pharmacology , Fibrosis/genetics , Fibrosis/physiopathology , Immunohistochemistry , Kidney Tubules/metabolism , Kidney Tubules/pathology , Mice , Mice, Transgenic , PAX8 Transcription Factor , Paired Box Transcription Factors/genetics , Polycystic Kidney Diseases/physiopathology , Promoter Regions, Genetic/genetics , Trans-Activators/metabolism , Transforming Growth Factor beta1/metabolism , Tuberous Sclerosis Complex 1 Protein , Tumor Suppressor Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...